Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 6/2015

17.10.2015 | zertifizierte fortbildung

Metastasiertes, kastrationsresistentes Prostatakarzinom

Aktuelle Therapiemöglichkeiten individuell abwägen

verfasst von: Enno Storz, Margitta Retz, Robert Tauber, Jürgen E. Gschwend, Matthias M. Heck

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Für Patienten mit metastasiertem, kastrationsresistentem Prostatakarzinom gibt es zwar keine kurativen Behandlungsmöglichkeiten mehr. In den letzten Jahren sind allerdings einige neue Optionen hinzugekommen. Da eindeutige Daten zur optimalen Therapiesequenz noch ausstehen, gilt es bei der individuellen Therapieentscheidung, die Zulassungskriterien, das Nebenwirkungsprofil und natürlich die Patientenwünsche zu beachten.
Literatur
1.
Zurück zum Zitat Heidenreich A et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479.CrossRefPubMed Heidenreich A et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479.CrossRefPubMed
2.
Zurück zum Zitat James ND et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the „Docetaxel Era“: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–1038.CrossRefPubMed James ND et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the „Docetaxel Era“: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–1038.CrossRefPubMed
3.
Zurück zum Zitat EAU Guidelines on Prostate Cancer - Update March 2015. http://uroweb.org/guideline/prostate-cancer. EAU Guidelines on Prostate Cancer - Update March 2015. http://​uroweb.​org/​guideline/​prostate-cancer.​
4.
Zurück zum Zitat Sridhar SS et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014;65(2):289–299.CrossRefPubMed Sridhar SS et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014;65(2):289–299.CrossRefPubMed
6.
Zurück zum Zitat Rathkopf DE et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825.CrossRefPubMed Rathkopf DE et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825.CrossRefPubMed
9.
Zurück zum Zitat Scher HI et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012;367(13):1187–1197.CrossRefPubMed Scher HI et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012;367(13):1187–1197.CrossRefPubMed
11.
Zurück zum Zitat Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.CrossRefPubMed Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.CrossRefPubMed
12.
Zurück zum Zitat Ryan CJ et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.CrossRefPubMed Ryan CJ et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.CrossRefPubMed
13.
Zurück zum Zitat Petrylak DP et al. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. N Engl J Med. 2004;351(15):1513–1520.CrossRefPubMed Petrylak DP et al. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. N Engl J Med. 2004;351(15):1513–1520.CrossRefPubMed
14.
Zurück zum Zitat Tannock IF et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med. 2004;351(15):1502–1512.CrossRefPubMed Tannock IF et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med. 2004;351(15):1502–1512.CrossRefPubMed
15.
Zurück zum Zitat Kellokumpu-Lehtinen PL et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14(2):117–124.CrossRefPubMed Kellokumpu-Lehtinen PL et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14(2):117–124.CrossRefPubMed
16.
Zurück zum Zitat Di Lorenzo G et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011;107(2):234–239.CrossRefPubMed Di Lorenzo G et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011;107(2):234–239.CrossRefPubMed
17.
Zurück zum Zitat de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.CrossRefPubMed de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.CrossRefPubMed
18.
Zurück zum Zitat Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.CrossRefPubMed Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.CrossRefPubMed
19.
Zurück zum Zitat Parker C et al. Updated survival, quality of life (QOL) and safety data of radium-223 chloride (ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). Ann Oncol. 2012;23(Suppl9):Abstr 1926. Parker C et al. Updated survival, quality of life (QOL) and safety data of radium-223 chloride (ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). Ann Oncol. 2012;23(Suppl9):Abstr 1926.
20.
Zurück zum Zitat Armstrong AJ et al. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(24):6891–6901.PubMedCentralCrossRefPubMed Armstrong AJ et al. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(24):6891–6901.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Rathkopf DE et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–3530.PubMedCentralCrossRefPubMed Rathkopf DE et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–3530.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Weineisen M et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med. 2015;56(8):1169–1176.CrossRefPubMed Weineisen M et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med. 2015;56(8):1169–1176.CrossRefPubMed
24.
Zurück zum Zitat Zechmann CM et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280–1292.PubMedCentralCrossRefPubMed Zechmann CM et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280–1292.PubMedCentralCrossRefPubMed
Metadaten
Titel
Metastasiertes, kastrationsresistentes Prostatakarzinom
Aktuelle Therapiemöglichkeiten individuell abwägen
verfasst von
Enno Storz
Margitta Retz
Robert Tauber
Jürgen E. Gschwend
Matthias M. Heck
Publikationsdatum
17.10.2015
Verlag
Urban & Vogel
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 6/2015
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-015-0713-0

Weitere Artikel der Ausgabe 6/2015

InFo Hämatologie + Onkologie 6/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.